Research article · 27 Feb 2025
Short communicationPublished Dec 2021
Can Simvastatin reduce COPD exacerbations? A randomized double blind controlled study
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Several studies have shown that statins have beneficial effects in chronic obstructive pulmonary disease (COPD) regarding lung function decline, rates and severity of exacerbations, hospitalization and need for mechanical ventilation. We performed a randomized double-blind placebocontrolled single-center trial of simvastatin at a daily dose of 40 mg versus placebo in patients with Global Initiative for COPD criteria II-IV at a tertiary care pulmonology department in Austria. Scheduled treatment duration was 12 months and main outcome parameter was time to first exacerbation. Overall, 209 patients were enrolled. In the 105 patients taking simvastatin, time to first exacerbation was significantly longer compared to the 104 patients taking placebo: median 341 vs. 140 days, log-rank test p < 0.001. Hazard ratio for risk of first exacerbation for the simvastatin group was 0.51 (95% CI 0.34 – 0.75; p = 0.001). Rate of exacerbations was significantly lower with simvastatin: 103 (41%) vs. 147 (59%), p = 0.003. The annualized exacerbation rate was 1.45 per patient-year in the simvastatin group and 1.9 in the placebo group (IRR 0.77, 95% CI 0.60 to 0.99). We found no effect on quality of life, lung function, six-minute walk test and high-sensitivity C-reactive protein. More patients dropped out in the simvastatin group compared to the placebo group (39 vs. 29). In our single-center RCT, simvastatin at a dose of 40 mg daily significantly prolonged time to first COPD exacerbation and reduced exacerbation rate.
Subjects
Pulmonology & RespiratoryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 31 Jan 2025
Role of serum levels of Aspergillus-galactomannan antigen index in evaluating cause of acute exacerbation of COPD
Research article · 13 Jul 2020
Profile of COPD Patients Admitted for Acute Exacerbation at The Pulmonology Department of Fann, Dakar, Senegal
Research article · 8 Apr 2020
Acute Exacerbation Factors of Chronic Obstructive Pulmonary Disease (COPD) Identified in Patients Managed at the Fann Pneumology Department, Dakar, Senegal
Conference abstract · 2020
COPD 2019:Biomarkers predicting outcomes in Asthma exacerbation - Venkat Rajasurya - Decatur memorial Hospital
More from this journal
The newest in Journal of Pulmonary Medicine.
Editorial · Feb 2022
Prevention of Prolonged Air Leak after Video-Assisted Thoracoscopic Anatomical Resection: A New PerspectiveLungs Biology
Review article · Feb 2022
Vitamin K2-Stabilizing Lung Extracellular Matrix
Case report · Feb 2022
The Medicinal Leech Possesses All Mechanisms of Influence for Preventing Pathogenesis of SARSCoV-2
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pulmonary Medicine
- SubjectPulmonology & Respiratory
- BylineArticles whose byline prints “Peter Schenk”
- BylineArticles whose byline prints “Spiel A”
- BylineArticles whose byline prints “Hüttinger F”
- BylineArticles whose byline prints “Gmeiner M”
- BylineArticles whose byline prints “Fugger J”
- BylineArticles whose byline prints “Pichler M”
- BylineArticles whose byline prints “Pichler G”
- BylineArticles whose byline prints “Schmeikal S”

